cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Agios Pharmaceuticals Inc
8 own
14 watching
Current Price
$31.67
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,291.3M
52-Week High
52-Week High
35.50000
52-Week Low
52-Week Low
19.79500
Average Volume
Average Volume
0.7M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
1.6274
iconMarket Capitalization1,291.3M
icon52-Week High35.50000
icon52-Week Low19.79500
iconAverage Volume0.7M
iconDividend Yield--
iconP/E Ratio1.6274
What does the Agios Pharmaceuticals Inc do?
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Agios Pharmaceuticals Inc make?
News & Events about Agios Pharmaceuticals Inc.
Zolmax
9 months ago
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO Free Report) CFO Cecilia Jones sold 1,597 shares of the firms stock in a transaction on Friday, June 30th. The stock was sold at an average price of $28.36, for a total value of $45,290.92. Following the completion of the transaction, the chief financial ...
Zolmax
1 year ago
Agios Pharmaceuticals (NASDAQ:AGIO Get Rating) and Aileron Therapeutics (NASDAQ:ALRN Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, ...
PR Newswire
1 year ago
Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero PR Newswire EMERYVILLE, Calif...
InvestorPlace
1 year ago
InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio. The post 7 Biotech Stocks to Buy for 100% Returns appeared first on InvestorPlace...
Zolmax
1 year ago
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO Get Rating) Director David P. Schenkein sold 20,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, March 27th. The shares were sold at an average price of $22.15, for a total transaction of $443,000.00. Following the ...
Frequently Asked Questions
Frequently Asked Questions
What is Agios Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Agios Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Agios Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Agios Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Agios Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Agios Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Agios Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Agios Pharmaceuticals Inc?
plus_minus_icon
What percentage is Agios Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Agios Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$31.67
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
BeiGene Ltd
BeiGene Ltd
$148.56
$4.44 (3.08 %)
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$41.84
$-0.61 (-1.44 %)
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
$35.84
$0.36 (1.01 %)
MacroGenics, Inc.
MacroGenics, Inc.
$14.37
$-1.33 (-8.47 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
BeiGene Ltd
BeiGene Ltd
$148.56
$4.44 (3.08 %)
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$41.84
$-0.61 (-1.44 %)
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
$35.84
$0.36 (1.01 %)
MacroGenics, Inc.
MacroGenics, Inc.
$14.37
$-1.33 (-8.47 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00